Liso-Cel for Relapsed/Refractory LBCL in Second Line

home / approval-alert / liso-cel-for-relapsed-refractory-lbcl-in-second-line

$Liso-Cel for Relapsed/Refractory LBCL in Second Line$

Liso-Cel for Relapsed/Refractory LBCL in Second Line

In June 2022, the FDA approved lisocabtagene maraleucel as treatment for relapsed/refractory large B-cell lymphoma following 1 prior line of therapy.

Articles

$FDA Approves Liso-Cel for Second-Line Relapsed/Refractory LBCL$

FDA Approves Liso-Cel for Second-Line Relapsed/Refractory LBCL

June 25th 2022

Based on results from the phase 3 TRANSFORM trial, the FDA has approved lisocabtagene maraleucel for the second-line treatment of relapsed/refractory large B-cell lymphoma.

Videos

Catherine S. Diefenbach, MD, Talks Future of CAR T-cell Therapy Following Liso-Cel Approval in Second-Line LBCL

July 7th 2022

Catherine S. Diefenbach, MD, spoke about refining understanding of CAR T-cell therapies after the approval of lisocabtagene maraleucel for patients with relapsed/refractory large B-cell lymphoma.

$Catherine S. Diefenbach, MD, Discusses Gaps Filled by Approval of Liso-Cel in Second-Line Relapsed/Refractory LBCL$

Catherine S. Diefenbach, MD, Discusses Gaps Filled by Approval of Liso-Cel in Second-Line Relapsed/Refractory LBCL

July 1st 2022

Catherine S. Diefenbach, MD, spoke about the approval of lisocabtagene maraleucel for patients with relapsed/refractory large B-cell lymphoma who do not have chemotherapy-sensitive disease.

Do Not Sell My Personal Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777